Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Daniel Camprubí, Alex Almuedo-Riera, Helena Martí-Soler, Alex Soriano, Juan Carlos Hurtado, Carme Subirà, Berta Grau-Pujol, Alejandro Krolewiecki, Jose Muñoz
PLOS ONE, doi:10.1371/journal.pone.0242184
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
Author Contributions Conceptualization: Daniel Camprubı ´, Alex Almuedo-Riera, Alejandro Krolewiecki, Jose Muñoz. Data curation: Juan Carlos Hurtado, Carme Subirà. Formal analysis: Daniel Camprubı ´, Helena Martı ´-Soler. Investigation: Juan Carlos Hurtado, Jose Muñoz. Methodology: Daniel Camprubı ´, Alex Almuedo-Riera, Jose Muñoz. Writing -original draft: Daniel Camprubı ´, Jose Muñoz.
Writing -review & editing: Alex Almuedo-Riera, Helena Martı ´-Soler, Alex Soriano, Carme Subirà, Berta Grau-Pujol, Alejandro Krolewiecki, Jose Muñoz.
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19-preliminary report, New Engl J Med,
doi:10.1056/NEJMoa2007764Buonfrate, Salas-Coronas, Muñoz, Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial, Lancet Infect Dis,
doi:10.1016/S1473-3099%2819%2930289-0Chaccour, Hamman, Ramo ´n-Garcı ´a, Rabinovich, Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency, Am J Trop Med Hyg
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol,
doi:10.1177/009127002401382731Kamgno, Gardon, Gardon-Wendel, Adverse systemic reactions to treatment of onchocerciasiswith ivermectin at normal and high doses given annually or three-monthly, Trans R Soc TropMed Hyg,
doi:10.1016/j.trstmh.2003.10.018Momekov, Momekova, Ivermectin as a potential COVID-19 treatment from a pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Biotechnology & Biotechnological Equipment,
doi:10.1080/13102818.2020.1775118Muñoz, Ballester, Antonijoan, Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers, PLoS Negl Trop Dis,
doi:10.1371/journal.pntd.0006020Navarro, Camprubı, ´ndez, Safety of high-dose ivermectin: a systematic review and meta-analysis, J Antimicrob Chemother,
doi:10.1093/jac/dkz524Smit, Ochomo, Aljayyoussi, Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial), Clin Infect Dis,
doi:10.1093/cid/ciy1063The, Group, Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report, New Engl J Med,
doi:10.1056/NEJMoa2021436Wimmersberger, Coulibaly, Schulz, Efficacy and safety of ivermectin against Trichuris trichiura in preschool-aged and school-aged children: a randomized controlled dose-finding trial, Clin Infect Dis,
doi:10.1093/cid/ciy246´ndez, Buonfrate, Gomez-Junyent, Zammarchi, Bisoffi et al., Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries, Am J Trop Med Hyg,
doi:10.4269/ajtmh.16-0923{ 'indexed': {'date-parts': [[2024, 3, 8]], 'date-time': '2024-03-08T12:24:07Z', 'timestamp': 1709900647277},
'reference-count': 14,
'publisher': 'Public Library of Science (PLoS)',
'issue': '11',
'license': [ { 'start': { 'date-parts': [[2020, 11, 11]],
'date-time': '2020-11-11T00:00:00Z',
'timestamp': 1605052800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': ['www.plosone.org'], 'crossmark-restriction': False},
'abstract': '<jats:p>Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We '
'retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and '
'we compared clinical and microbiological outcomes with a similar group of patients not '
'receiving ivermectin. No differences were found between groups. We recommend the evaluation '
'of high-doses of ivermectin in randomized trials against SARS-CoV-2.</jats:p>',
'DOI': '10.1371/journal.pone.0242184',
'type': 'journal-article',
'created': { 'date-parts': [[2020, 11, 11]],
'date-time': '2020-11-11T18:40:53Z',
'timestamp': 1605120053000},
'page': 'e0242184',
'update-policy': 'http://dx.doi.org/10.1371/journal.pone.corrections_policy',
'source': 'Crossref',
'is-referenced-by-count': 43,
'title': 'Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients',
'prefix': '10.1371',
'volume': '15',
'author': [ {'given': 'Daniel', 'family': 'Camprubí', 'sequence': 'first', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-4643-4456',
'authenticated-orcid': True,
'given': 'Alex',
'family': 'Almuedo-Riera',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-7127-205X',
'authenticated-orcid': True,
'given': 'Helena',
'family': 'Martí-Soler',
'sequence': 'additional',
'affiliation': []},
{'given': 'Alex', 'family': 'Soriano', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-9519-6082',
'authenticated-orcid': True,
'given': 'Juan Carlos',
'family': 'Hurtado',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-6246-8501',
'authenticated-orcid': True,
'given': 'Carme',
'family': 'Subirà',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-7320-0965',
'authenticated-orcid': True,
'given': 'Berta',
'family': 'Grau-Pujol',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-9054-1211',
'authenticated-orcid': True,
'given': 'Alejandro',
'family': 'Krolewiecki',
'sequence': 'additional',
'affiliation': []},
{'given': 'Jose', 'family': 'Muñoz', 'sequence': 'additional', 'affiliation': []}],
'member': '340',
'published-online': {'date-parts': [[2020, 11, 11]]},
'reference': [ { 'key': 'pone.0242184.ref001',
'author': 'The RECOVERY Collaborative Group',
'journal-title': 'New Engl J Med'},
{ 'key': 'pone.0242184.ref002',
'article-title': 'Remdesivir for the treatment of Covid-19—preliminary report',
'author': 'JH Beigel',
'year': '2020',
'journal-title': 'New Engl J Med'},
{ 'key': 'pone.0242184.ref003',
'article-title': 'Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A '
'Review',
'author': 'JM Sanders',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'pone.0242184.ref004',
'first-page': '104787',
'article-title': 'The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 '
'in vitro',
'volume': '2020',
'author': 'L Caly',
'journal-title': 'Antiviral Res.'},
{ 'key': 'pone.0242184.ref005',
'first-page': '1',
'article-title': 'Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in '
'Times of Urgency',
'author': 'C Chaccour',
'year': '2020',
'journal-title': 'Am J Trop Med Hyg'},
{ 'issue': '3',
'key': 'pone.0242184.ref006',
'doi-asserted-by': 'crossref',
'first-page': '645',
'DOI': '10.4269/ajtmh.16-0923',
'article-title': 'Evidence-Based Guidelines for Screening and Management of '
'Strongyloidiasis in Non-Endemic Countries',
'volume': '97',
'author': 'A Requena-Méndez',
'year': '2017',
'journal-title': 'Am J Trop Med Hyg.'},
{ 'issue': '4',
'key': 'pone.0242184.ref007',
'doi-asserted-by': 'crossref',
'first-page': '827',
'DOI': '10.1093/jac/dkz524',
'article-title': 'Safety of high-dose ivermectin: a systematic review and meta-analysis',
'volume': '75',
'author': 'M Navarro',
'year': '2020',
'journal-title': 'J Antimicrob Chemother.'},
{ 'issue': '1',
'key': 'pone.0242184.ref008',
'doi-asserted-by': 'crossref',
'first-page': 'e0006020',
'DOI': '10.1371/journal.pntd.0006020',
'article-title': 'Safety and pharmacokinetic profile of fixed-dose ivermectin with an '
'innovative 18mg tablet in healthy adult volunteers',
'volume': '12',
'author': 'J Muñoz',
'year': '2018',
'journal-title': 'PLoS Negl Trop Dis'},
{ 'key': 'pone.0242184.ref009',
'doi-asserted-by': 'crossref',
'first-page': '1247',
'DOI': '10.1093/cid/ciy246',
'article-title': 'Efficacy and safety of ivermectin against Trichuris trichiura in '
'preschool-aged and school-aged children: a randomized controlled '
'dose-finding trial',
'volume': '67',
'author': 'D Wimmersberger',
'year': '2018',
'journal-title': 'Clin Infect Dis'},
{ 'issue': '11',
'key': 'pone.0242184.ref010',
'doi-asserted-by': 'crossref',
'first-page': '1181',
'DOI': '10.1016/S1473-3099(19)30289-0',
'article-title': 'Multiple-dose versus single-dose ivermectin for Strongyloides '
'stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, '
'phase 3, randomised controlled superiority trial',
'volume': '19',
'author': 'D Buonfrate',
'year': '2019',
'journal-title': 'Lancet Infect Dis'},
{ 'issue': '7',
'key': 'pone.0242184.ref011',
'doi-asserted-by': 'crossref',
'first-page': '1112',
'DOI': '10.1093/cid/ciy1063',
'article-title': 'Human Direct Skin Feeding Versus Membrane Feeding to Assess the '
'Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial)',
'volume': '69',
'author': 'MR Smit',
'year': '2019',
'journal-title': 'Clin Infect Dis.'},
{ 'key': 'pone.0242184.ref012',
'doi-asserted-by': 'crossref',
'first-page': '496',
'DOI': '10.1016/j.trstmh.2003.10.018',
'article-title': 'Adverse systemic reactions to treatment of onchocerciasiswith '
'ivermectin at normal and high doses given annually or three-monthly',
'volume': '98',
'author': 'J Kamgno',
'year': '2004',
'journal-title': 'Trans R Soc TropMed Hyg'},
{ 'key': 'pone.0242184.ref013',
'doi-asserted-by': 'crossref',
'first-page': '1122',
'DOI': '10.1177/009127002401382731',
'article-title': 'Safety, tolerability, and pharmacokinetics of escalating high doses of '
'ivermectin in healthy adult subjects',
'volume': '42',
'author': 'CA Guzzo',
'year': '2002',
'journal-title': 'J Clin Pharmacol'},
{ 'key': 'pone.0242184.ref014',
'first-page': '1, 469',
'article-title': 'Ivermectin as a potential COVID-19 treatment from a pharmacokinetic '
'point of view: antiviral levels are not likely attainable with known '
'dosing regimens',
'volume': '34',
'author': 'G Momekov',
'journal-title': 'Biotechnology & Biotechnological Equipment'}],
'container-title': 'PLOS ONE',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://dx.plos.org/10.1371/journal.pone.0242184',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2020, 11, 11]],
'date-time': '2020-11-11T18:41:12Z',
'timestamp': 1605120072000},
'score': 1,
'resource': {'primary': {'URL': 'https://dx.plos.org/10.1371/journal.pone.0242184'}},
'subtitle': [],
'editor': [{'given': 'Thomas P.C.', 'family': 'Dorlo', 'sequence': 'first', 'affiliation': []}],
'short-title': [],
'issued': {'date-parts': [[2020, 11, 11]]},
'references-count': 14,
'journal-issue': {'issue': '11', 'published-online': {'date-parts': [[2020, 11, 11]]}},
'URL': 'http://dx.doi.org/10.1371/journal.pone.0242184',
'relation': {},
'ISSN': ['1932-6203'],
'subject': ['Multidisciplinary'],
'container-title-short': 'PLoS ONE',
'published': {'date-parts': [[2020, 11, 11]]}}
